{"id":46565,"date":"2020-06-17T11:34:53","date_gmt":"2020-06-17T11:34:53","guid":{"rendered":"https:\/\/parkinson.ca\/sunovion-annonce-lapprobation-par-sante-canada-du-film-soluble-kynmobi-chlorhydrate-dapomorphine-pour-le-traitement-des-episodes-darret-de-la-maladie-de-parkinson\/"},"modified":"2025-01-17T23:07:58","modified_gmt":"2025-01-17T23:07:58","slug":"sunovion-annonce-lapprobation-par-sante-canada-du-film-soluble-kynmobi-chlorhydrate-dapomorphine-pour-le-traitement-des-episodes-darret-de-la-maladie-de-parkinson","status":"publish","type":"post","link":"https:\/\/www.parkinson.ca\/fr\/sunovion-annonce-lapprobation-par-sante-canada-du-film-soluble-kynmobi-chlorhydrate-dapomorphine-pour-le-traitement-des-episodes-darret-de-la-maladie-de-parkinson\/","title":{"rendered":"Sunovion annonce l&rsquo;approbation par Sant\u00e9 Canada du film soluble KYNMOBI\u2122 (chlorhydrate d&rsquo;apomorphine) pour le traitement des \u00e9pisodes d&rsquo;arr\u00eat de la maladie de Parkinson."},"content":{"rendered":"<p>MISSISSAUGA, Ontario&#8211;(BUSINESS WIRE)&#8211; Sunovion Pharmaceuticals Inc. (Sunovion) a annonc\u00e9 aujourd&rsquo;hui que Sant\u00e9 Canada a approuv\u00e9 KYNMOBI\u2122 (apomorphine HCI) film soluble pour le traitement aigu et intermittent des \u00e9pisodes OFF chez les patients atteints de la maladie de Parkinson (MP). Les \u00e9pisodes OFF correspondent \u00e0 la r\u00e9apparition ou \u00e0 l&rsquo;aggravation des sympt\u00f4mes de la maladie de Parkinson, par ailleurs contr\u00f4l\u00e9s par la l\u00e9vodopa\/carbidopa par voie orale. Ils peuvent \u00eatre caract\u00e9ris\u00e9s, en partie, par des tremblements, une raideur, un ralentissement des mouvements ou d&rsquo;autres sympt\u00f4mes. Ces \u00e9pisodes perturbateurs peuvent survenir \u00e0 tout moment de la journ\u00e9e et s&rsquo;aggravent au fur et \u00e0 mesure de l&rsquo;\u00e9volution de la maladie. KYNMOBI a \u00e9t\u00e9 approuv\u00e9 par la Food and Drug Administration (FDA) le 21 mai 2020. \u00ab\u00a0Au fur et \u00e0 mesure que la maladie \u00e9volue, les patients atteints de la maladie de Parkinson doivent faire face \u00e0 des \u00e9pisodes difficiles et perturbateurs d&rsquo;ARR\u00caT qui s&rsquo;accompagnent d&rsquo;une mobilit\u00e9 r\u00e9duite \u00ab\u00a0, a d\u00e9clar\u00e9 Karen Lee, PhD, directrice g\u00e9n\u00e9rale de Parkinson Canada. \u00ab\u00a0L&rsquo;approbation accord\u00e9e aujourd&rsquo;hui par Sant\u00e9 Canada constitue un important pas en avant pour les personnes vivant avec la maladie de Parkinson, car elles disposent maintenant d&rsquo;un plus grand nombre d&rsquo;options pour les aider \u00e0 g\u00e9rer les effets des \u00e9pisodes OFF lorsqu&rsquo;ils se produisent.\u00a0\u00bb Pour lire le communiqu\u00e9 de presse dans son int\u00e9gralit\u00e9, visitez le site https:\/\/news.sunovion.com\/press-releases\/.      <\/p>\n","protected":false},"excerpt":{"rendered":"<p>MISSISSAUGA, Ontario&#8211;(BUSINESS WIRE)&#8211; Sunovion Pharmaceuticals Inc. (Sunovion) a annonc\u00e9 aujourd&rsquo;hui que Sant\u00e9 Canada a approuv\u00e9 KYNMOBI\u2122 (apomorphine HCI) film soluble pour le traitement aigu et intermittent des \u00e9pisodes OFF chez les patients atteints de la maladie de Parkinson (MP). Les \u00e9pisodes OFF correspondent \u00e0 la r\u00e9apparition ou \u00e0 l&rsquo;aggravation des sympt\u00f4mes de la maladie de [&hellip;]<\/p>\n","protected":false},"author":67,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[140],"tags":[],"audience":[],"class_list":["post-46565","post","type-post","status-publish","format-standard","hentry","category-non-classe"],"acf":[],"aioseo_notices":[],"aioseo_head":"\n\t\t<!-- All in One SEO 4.9.10 - aioseo.com -->\n\t<meta name=\"description\" content=\"MISSISSAUGA, Ontario--(BUSINESS WIRE)-- Sunovion Pharmaceuticals Inc. (Sunovion) a annonc\u00e9 aujourd&#039;hui que Sant\u00e9 Canada a approuv\u00e9 KYNMOBI\u2122 (apomorphine HCI) film soluble pour le traitement aigu et intermittent des \u00e9pisodes OFF chez les patients atteints de la maladie de Parkinson (MP). Les \u00e9pisodes OFF correspondent \u00e0 la r\u00e9apparition ou \u00e0 l&#039;aggravation des sympt\u00f4mes de la maladie de\" \/>\n\t<meta name=\"robots\" content=\"max-image-preview:large\" \/>\n\t<meta name=\"author\" content=\"deactivatedusers\"\/>\n\t<meta name=\"google-site-verification\" content=\"2AhivUiST2eKQcfei6JBM5Zbf8YQRvHy0kRBp9sDLWo\" \/>\n\t<link rel=\"canonical\" href=\"https:\/\/www.parkinson.ca\/fr\/sunovion-annonce-lapprobation-par-sante-canada-du-film-soluble-kynmobi-chlorhydrate-dapomorphine-pour-le-traitement-des-episodes-darret-de-la-maladie-de-parkinson\/\" \/>\n\t<meta name=\"generator\" content=\"All in One SEO (AIOSEO) 4.9.10\" \/>\n\t\t<meta property=\"og:locale\" content=\"fr_FR\" \/>\n\t\t<meta property=\"og:site_name\" content=\"Parkinson Canada -\" \/>\n\t\t<meta property=\"og:type\" content=\"article\" \/>\n\t\t<meta property=\"og:title\" content=\"Sunovion annonce l\u2019approbation par Sant\u00e9 Canada du film soluble KYNMOBI\u2122 (chlorhydrate d\u2019apomorphine) pour le traitement des \u00e9pisodes d\u2019arr\u00eat de la maladie de Parkinson. - Parkinson Canada\" \/>\n\t\t<meta property=\"og:description\" content=\"MISSISSAUGA, Ontario--(BUSINESS WIRE)-- Sunovion Pharmaceuticals Inc. (Sunovion) a annonc\u00e9 aujourd&#039;hui que Sant\u00e9 Canada a approuv\u00e9 KYNMOBI\u2122 (apomorphine HCI) film soluble pour le traitement aigu et intermittent des \u00e9pisodes OFF chez les patients atteints de la maladie de Parkinson (MP). Les \u00e9pisodes OFF correspondent \u00e0 la r\u00e9apparition ou \u00e0 l&#039;aggravation des sympt\u00f4mes de la maladie de\" \/>\n\t\t<meta property=\"og:url\" content=\"https:\/\/www.parkinson.ca\/fr\/sunovion-annonce-lapprobation-par-sante-canada-du-film-soluble-kynmobi-chlorhydrate-dapomorphine-pour-le-traitement-des-episodes-darret-de-la-maladie-de-parkinson\/\" \/>\n\t\t<meta property=\"og:image\" content=\"https:\/\/www.parkinson.ca\/wp-content\/uploads\/2025\/02\/Parkinson-Canada-featured-image.png\" \/>\n\t\t<meta property=\"og:image:secure_url\" content=\"https:\/\/www.parkinson.ca\/wp-content\/uploads\/2025\/02\/Parkinson-Canada-featured-image.png\" \/>\n\t\t<meta property=\"og:image:width\" content=\"1000\" \/>\n\t\t<meta property=\"og:image:height\" content=\"600\" \/>\n\t\t<meta property=\"article:published_time\" content=\"2020-06-17T11:34:53+00:00\" \/>\n\t\t<meta property=\"article:modified_time\" content=\"2025-01-17T23:07:58+00:00\" \/>\n\t\t<meta property=\"article:publisher\" content=\"https:\/\/facebook.com\/parkinsoncanada\" \/>\n\t\t<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n\t\t<meta name=\"twitter:site\" content=\"@parkinsoncanada\" \/>\n\t\t<meta name=\"twitter:title\" content=\"Sunovion annonce l\u2019approbation par Sant\u00e9 Canada du film soluble KYNMOBI\u2122 (chlorhydrate d\u2019apomorphine) pour le traitement des \u00e9pisodes d\u2019arr\u00eat de la maladie de Parkinson. - Parkinson Canada\" \/>\n\t\t<meta name=\"twitter:description\" content=\"MISSISSAUGA, Ontario--(BUSINESS WIRE)-- Sunovion Pharmaceuticals Inc. (Sunovion) a annonc\u00e9 aujourd&#039;hui que Sant\u00e9 Canada a approuv\u00e9 KYNMOBI\u2122 (apomorphine HCI) film soluble pour le traitement aigu et intermittent des \u00e9pisodes OFF chez les patients atteints de la maladie de Parkinson (MP). Les \u00e9pisodes OFF correspondent \u00e0 la r\u00e9apparition ou \u00e0 l&#039;aggravation des sympt\u00f4mes de la maladie de\" \/>\n\t\t<meta name=\"twitter:creator\" content=\"@parkinsoncanada\" \/>\n\t\t<meta name=\"twitter:image\" content=\"https:\/\/www.parkinson.ca\/wp-content\/uploads\/2025\/02\/Parkinson-Canada-featured-image.png\" \/>\n\t\t<script type=\"application\/ld+json\" class=\"aioseo-schema\">\n\t\t\t{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"BlogPosting\",\"@id\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/sunovion-annonce-lapprobation-par-sante-canada-du-film-soluble-kynmobi-chlorhydrate-dapomorphine-pour-le-traitement-des-episodes-darret-de-la-maladie-de-parkinson\\\/#blogposting\",\"name\":\"Sunovion annonce l\\u2019approbation par Sant\\u00e9 Canada du film soluble KYNMOBI\\u2122 (chlorhydrate d\\u2019apomorphine) pour le traitement des \\u00e9pisodes d\\u2019arr\\u00eat de la maladie de Parkinson. - Parkinson Canada\",\"headline\":\"Sunovion annonce l&rsquo;approbation par Sant\\u00e9 Canada du film soluble KYNMOBI\\u2122 (chlorhydrate d&rsquo;apomorphine) pour le traitement des \\u00e9pisodes d&rsquo;arr\\u00eat de la maladie de Parkinson.\",\"author\":{\"@id\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/author\\\/deactivatedusers\\\/#author\"},\"publisher\":{\"@id\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/#organization\"},\"image\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/parkinson.ca\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/Parkinson-Canada-logo-23-RGB.jpg\",\"@id\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/#articleImage\"},\"datePublished\":\"2020-06-17T11:34:53+00:00\",\"dateModified\":\"2025-01-17T23:07:58+00:00\",\"inLanguage\":\"fr-FR\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/sunovion-annonce-lapprobation-par-sante-canada-du-film-soluble-kynmobi-chlorhydrate-dapomorphine-pour-le-traitement-des-episodes-darret-de-la-maladie-de-parkinson\\\/#webpage\"},\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/sunovion-annonce-lapprobation-par-sante-canada-du-film-soluble-kynmobi-chlorhydrate-dapomorphine-pour-le-traitement-des-episodes-darret-de-la-maladie-de-parkinson\\\/#webpage\"},\"articleSection\":\"Non class\\u00e9, Facultatif\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/sunovion-annonce-lapprobation-par-sante-canada-du-film-soluble-kynmobi-chlorhydrate-dapomorphine-pour-le-traitement-des-episodes-darret-de-la-maladie-de-parkinson\\\/#breadcrumblist\",\"itemListElement\":[{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/#listItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/category\\\/non-classe\\\/#listItem\",\"name\":\"Non class\\u00e9\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/category\\\/non-classe\\\/#listItem\",\"position\":2,\"name\":\"Non class\\u00e9\",\"item\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/category\\\/non-classe\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/sunovion-annonce-lapprobation-par-sante-canada-du-film-soluble-kynmobi-chlorhydrate-dapomorphine-pour-le-traitement-des-episodes-darret-de-la-maladie-de-parkinson\\\/#listItem\",\"name\":\"Sunovion annonce l&rsquo;approbation par Sant\\u00e9 Canada du film soluble KYNMOBI\\u2122 (chlorhydrate d&rsquo;apomorphine) pour le traitement des \\u00e9pisodes d&rsquo;arr\\u00eat de la maladie de Parkinson.\"},\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/#listItem\",\"name\":\"Home\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/sunovion-annonce-lapprobation-par-sante-canada-du-film-soluble-kynmobi-chlorhydrate-dapomorphine-pour-le-traitement-des-episodes-darret-de-la-maladie-de-parkinson\\\/#listItem\",\"position\":3,\"name\":\"Sunovion annonce l&rsquo;approbation par Sant\\u00e9 Canada du film soluble KYNMOBI\\u2122 (chlorhydrate d&rsquo;apomorphine) pour le traitement des \\u00e9pisodes d&rsquo;arr\\u00eat de la maladie de Parkinson.\",\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/category\\\/non-classe\\\/#listItem\",\"name\":\"Non class\\u00e9\"}}]},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/#organization\",\"name\":\"Parkinson Canada\",\"description\":\"Parkinson Canada empowers people living with Parkinson\\u2019s and their care partners to thrive. Through advocacy, education, and support, we work to improve access to care, advance research, and build a stronger Parkinson\\u2019s community across Canada. Join us in making a difference.\",\"url\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/\",\"email\":\"info@parkinson.ca\",\"telephone\":\"+18005653000\",\"foundingDate\":\"1965-04-11\",\"numberOfEmployees\":{\"@type\":\"QuantitativeValue\",\"minValue\":50,\"maxValue\":100},\"logo\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/parkinson.ca\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/Parkinson-Canada-logo-23-RGB.jpg\",\"@id\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/sunovion-annonce-lapprobation-par-sante-canada-du-film-soluble-kynmobi-chlorhydrate-dapomorphine-pour-le-traitement-des-episodes-darret-de-la-maladie-de-parkinson\\\/#organizationLogo\"},\"image\":{\"@id\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/sunovion-annonce-lapprobation-par-sante-canada-du-film-soluble-kynmobi-chlorhydrate-dapomorphine-pour-le-traitement-des-episodes-darret-de-la-maladie-de-parkinson\\\/#organizationLogo\"},\"sameAs\":[\"https:\\\/\\\/facebook.com\\\/parkinsoncanada\",\"https:\\\/\\\/twitter.com\\\/parkinsoncanada\",\"https:\\\/\\\/instagram.com\\\/parkinsoncanada\",\"https:\\\/\\\/www.youtube.com\\\/channel\\\/UCm_sAjRqhAaiutx2B9dOqng\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/parkinson-canada\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/author\\\/deactivatedusers\\\/#author\",\"url\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/author\\\/deactivatedusers\\\/\",\"name\":\"deactivatedusers\",\"image\":{\"@type\":\"ImageObject\",\"@id\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/sunovion-annonce-lapprobation-par-sante-canada-du-film-soluble-kynmobi-chlorhydrate-dapomorphine-pour-le-traitement-des-episodes-darret-de-la-maladie-de-parkinson\\\/#authorImage\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/95f7b1c92619f8d7f57334f62167ff8f34a7c05721a4842802e3e6125c94fcfe?s=96&d=mm&r=g\",\"width\":96,\"height\":96,\"caption\":\"deactivatedusers\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/sunovion-annonce-lapprobation-par-sante-canada-du-film-soluble-kynmobi-chlorhydrate-dapomorphine-pour-le-traitement-des-episodes-darret-de-la-maladie-de-parkinson\\\/#webpage\",\"url\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/sunovion-annonce-lapprobation-par-sante-canada-du-film-soluble-kynmobi-chlorhydrate-dapomorphine-pour-le-traitement-des-episodes-darret-de-la-maladie-de-parkinson\\\/\",\"name\":\"Sunovion annonce l\\u2019approbation par Sant\\u00e9 Canada du film soluble KYNMOBI\\u2122 (chlorhydrate d\\u2019apomorphine) pour le traitement des \\u00e9pisodes d\\u2019arr\\u00eat de la maladie de Parkinson. - Parkinson Canada\",\"description\":\"MISSISSAUGA, Ontario--(BUSINESS WIRE)-- Sunovion Pharmaceuticals Inc. (Sunovion) a annonc\\u00e9 aujourd'hui que Sant\\u00e9 Canada a approuv\\u00e9 KYNMOBI\\u2122 (apomorphine HCI) film soluble pour le traitement aigu et intermittent des \\u00e9pisodes OFF chez les patients atteints de la maladie de Parkinson (MP). Les \\u00e9pisodes OFF correspondent \\u00e0 la r\\u00e9apparition ou \\u00e0 l'aggravation des sympt\\u00f4mes de la maladie de\",\"inLanguage\":\"fr-FR\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/#website\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/sunovion-annonce-lapprobation-par-sante-canada-du-film-soluble-kynmobi-chlorhydrate-dapomorphine-pour-le-traitement-des-episodes-darret-de-la-maladie-de-parkinson\\\/#breadcrumblist\"},\"author\":{\"@id\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/author\\\/deactivatedusers\\\/#author\"},\"creator\":{\"@id\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/author\\\/deactivatedusers\\\/#author\"},\"datePublished\":\"2020-06-17T11:34:53+00:00\",\"dateModified\":\"2025-01-17T23:07:58+00:00\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/\",\"name\":\"Parkinson Canada\",\"inLanguage\":\"fr-FR\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.parkinson.ca\\\/fr\\\/#organization\"}}]}\n\t\t<\/script>\n\t\t<!-- All in One SEO -->\n\n","aioseo_head_json":{"title":"Sunovion annonce l\u2019approbation par Sant\u00e9 Canada du film soluble KYNMOBI\u2122 (chlorhydrate d\u2019apomorphine) pour le traitement des \u00e9pisodes d\u2019arr\u00eat de la maladie de Parkinson. - Parkinson Canada","description":"MISSISSAUGA, Ontario--(BUSINESS WIRE)-- Sunovion Pharmaceuticals Inc. (Sunovion) a annonc\u00e9 aujourd'hui que Sant\u00e9 Canada a approuv\u00e9 KYNMOBI\u2122 (apomorphine HCI) film soluble pour le traitement aigu et intermittent des \u00e9pisodes OFF chez les patients atteints de la maladie de Parkinson (MP). Les \u00e9pisodes OFF correspondent \u00e0 la r\u00e9apparition ou \u00e0 l'aggravation des sympt\u00f4mes de la maladie de","canonical_url":"https:\/\/www.parkinson.ca\/fr\/sunovion-annonce-lapprobation-par-sante-canada-du-film-soluble-kynmobi-chlorhydrate-dapomorphine-pour-le-traitement-des-episodes-darret-de-la-maladie-de-parkinson\/","robots":"max-image-preview:large","keywords":"","webmasterTools":{"google-site-verification":"2AhivUiST2eKQcfei6JBM5Zbf8YQRvHy0kRBp9sDLWo","miscellaneous":""},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"BlogPosting","@id":"https:\/\/www.parkinson.ca\/fr\/sunovion-annonce-lapprobation-par-sante-canada-du-film-soluble-kynmobi-chlorhydrate-dapomorphine-pour-le-traitement-des-episodes-darret-de-la-maladie-de-parkinson\/#blogposting","name":"Sunovion annonce l\u2019approbation par Sant\u00e9 Canada du film soluble KYNMOBI\u2122 (chlorhydrate d\u2019apomorphine) pour le traitement des \u00e9pisodes d\u2019arr\u00eat de la maladie de Parkinson. - Parkinson Canada","headline":"Sunovion annonce l&rsquo;approbation par Sant\u00e9 Canada du film soluble KYNMOBI\u2122 (chlorhydrate d&rsquo;apomorphine) pour le traitement des \u00e9pisodes d&rsquo;arr\u00eat de la maladie de Parkinson.","author":{"@id":"https:\/\/www.parkinson.ca\/fr\/author\/deactivatedusers\/#author"},"publisher":{"@id":"https:\/\/www.parkinson.ca\/fr\/#organization"},"image":{"@type":"ImageObject","url":"https:\/\/parkinson.ca\/wp-content\/uploads\/2025\/01\/Parkinson-Canada-logo-23-RGB.jpg","@id":"https:\/\/www.parkinson.ca\/fr\/#articleImage"},"datePublished":"2020-06-17T11:34:53+00:00","dateModified":"2025-01-17T23:07:58+00:00","inLanguage":"fr-FR","mainEntityOfPage":{"@id":"https:\/\/www.parkinson.ca\/fr\/sunovion-annonce-lapprobation-par-sante-canada-du-film-soluble-kynmobi-chlorhydrate-dapomorphine-pour-le-traitement-des-episodes-darret-de-la-maladie-de-parkinson\/#webpage"},"isPartOf":{"@id":"https:\/\/www.parkinson.ca\/fr\/sunovion-annonce-lapprobation-par-sante-canada-du-film-soluble-kynmobi-chlorhydrate-dapomorphine-pour-le-traitement-des-episodes-darret-de-la-maladie-de-parkinson\/#webpage"},"articleSection":"Non class\u00e9, Facultatif"},{"@type":"BreadcrumbList","@id":"https:\/\/www.parkinson.ca\/fr\/sunovion-annonce-lapprobation-par-sante-canada-du-film-soluble-kynmobi-chlorhydrate-dapomorphine-pour-le-traitement-des-episodes-darret-de-la-maladie-de-parkinson\/#breadcrumblist","itemListElement":[{"@type":"ListItem","@id":"https:\/\/www.parkinson.ca\/fr\/#listItem","position":1,"name":"Home","item":"https:\/\/www.parkinson.ca\/fr\/","nextItem":{"@type":"ListItem","@id":"https:\/\/www.parkinson.ca\/fr\/category\/non-classe\/#listItem","name":"Non class\u00e9"}},{"@type":"ListItem","@id":"https:\/\/www.parkinson.ca\/fr\/category\/non-classe\/#listItem","position":2,"name":"Non class\u00e9","item":"https:\/\/www.parkinson.ca\/fr\/category\/non-classe\/","nextItem":{"@type":"ListItem","@id":"https:\/\/www.parkinson.ca\/fr\/sunovion-annonce-lapprobation-par-sante-canada-du-film-soluble-kynmobi-chlorhydrate-dapomorphine-pour-le-traitement-des-episodes-darret-de-la-maladie-de-parkinson\/#listItem","name":"Sunovion annonce l&rsquo;approbation par Sant\u00e9 Canada du film soluble KYNMOBI\u2122 (chlorhydrate d&rsquo;apomorphine) pour le traitement des \u00e9pisodes d&rsquo;arr\u00eat de la maladie de Parkinson."},"previousItem":{"@type":"ListItem","@id":"https:\/\/www.parkinson.ca\/fr\/#listItem","name":"Home"}},{"@type":"ListItem","@id":"https:\/\/www.parkinson.ca\/fr\/sunovion-annonce-lapprobation-par-sante-canada-du-film-soluble-kynmobi-chlorhydrate-dapomorphine-pour-le-traitement-des-episodes-darret-de-la-maladie-de-parkinson\/#listItem","position":3,"name":"Sunovion annonce l&rsquo;approbation par Sant\u00e9 Canada du film soluble KYNMOBI\u2122 (chlorhydrate d&rsquo;apomorphine) pour le traitement des \u00e9pisodes d&rsquo;arr\u00eat de la maladie de Parkinson.","previousItem":{"@type":"ListItem","@id":"https:\/\/www.parkinson.ca\/fr\/category\/non-classe\/#listItem","name":"Non class\u00e9"}}]},{"@type":"Organization","@id":"https:\/\/www.parkinson.ca\/fr\/#organization","name":"Parkinson Canada","description":"Parkinson Canada empowers people living with Parkinson\u2019s and their care partners to thrive. Through advocacy, education, and support, we work to improve access to care, advance research, and build a stronger Parkinson\u2019s community across Canada. Join us in making a difference.","url":"https:\/\/www.parkinson.ca\/fr\/","email":"info@parkinson.ca","telephone":"+18005653000","foundingDate":"1965-04-11","numberOfEmployees":{"@type":"QuantitativeValue","minValue":50,"maxValue":100},"logo":{"@type":"ImageObject","url":"https:\/\/parkinson.ca\/wp-content\/uploads\/2025\/01\/Parkinson-Canada-logo-23-RGB.jpg","@id":"https:\/\/www.parkinson.ca\/fr\/sunovion-annonce-lapprobation-par-sante-canada-du-film-soluble-kynmobi-chlorhydrate-dapomorphine-pour-le-traitement-des-episodes-darret-de-la-maladie-de-parkinson\/#organizationLogo"},"image":{"@id":"https:\/\/www.parkinson.ca\/fr\/sunovion-annonce-lapprobation-par-sante-canada-du-film-soluble-kynmobi-chlorhydrate-dapomorphine-pour-le-traitement-des-episodes-darret-de-la-maladie-de-parkinson\/#organizationLogo"},"sameAs":["https:\/\/facebook.com\/parkinsoncanada","https:\/\/twitter.com\/parkinsoncanada","https:\/\/instagram.com\/parkinsoncanada","https:\/\/www.youtube.com\/channel\/UCm_sAjRqhAaiutx2B9dOqng","https:\/\/www.linkedin.com\/company\/parkinson-canada"]},{"@type":"Person","@id":"https:\/\/www.parkinson.ca\/fr\/author\/deactivatedusers\/#author","url":"https:\/\/www.parkinson.ca\/fr\/author\/deactivatedusers\/","name":"deactivatedusers","image":{"@type":"ImageObject","@id":"https:\/\/www.parkinson.ca\/fr\/sunovion-annonce-lapprobation-par-sante-canada-du-film-soluble-kynmobi-chlorhydrate-dapomorphine-pour-le-traitement-des-episodes-darret-de-la-maladie-de-parkinson\/#authorImage","url":"https:\/\/secure.gravatar.com\/avatar\/95f7b1c92619f8d7f57334f62167ff8f34a7c05721a4842802e3e6125c94fcfe?s=96&d=mm&r=g","width":96,"height":96,"caption":"deactivatedusers"}},{"@type":"WebPage","@id":"https:\/\/www.parkinson.ca\/fr\/sunovion-annonce-lapprobation-par-sante-canada-du-film-soluble-kynmobi-chlorhydrate-dapomorphine-pour-le-traitement-des-episodes-darret-de-la-maladie-de-parkinson\/#webpage","url":"https:\/\/www.parkinson.ca\/fr\/sunovion-annonce-lapprobation-par-sante-canada-du-film-soluble-kynmobi-chlorhydrate-dapomorphine-pour-le-traitement-des-episodes-darret-de-la-maladie-de-parkinson\/","name":"Sunovion annonce l\u2019approbation par Sant\u00e9 Canada du film soluble KYNMOBI\u2122 (chlorhydrate d\u2019apomorphine) pour le traitement des \u00e9pisodes d\u2019arr\u00eat de la maladie de Parkinson. - Parkinson Canada","description":"MISSISSAUGA, Ontario--(BUSINESS WIRE)-- Sunovion Pharmaceuticals Inc. (Sunovion) a annonc\u00e9 aujourd'hui que Sant\u00e9 Canada a approuv\u00e9 KYNMOBI\u2122 (apomorphine HCI) film soluble pour le traitement aigu et intermittent des \u00e9pisodes OFF chez les patients atteints de la maladie de Parkinson (MP). Les \u00e9pisodes OFF correspondent \u00e0 la r\u00e9apparition ou \u00e0 l'aggravation des sympt\u00f4mes de la maladie de","inLanguage":"fr-FR","isPartOf":{"@id":"https:\/\/www.parkinson.ca\/fr\/#website"},"breadcrumb":{"@id":"https:\/\/www.parkinson.ca\/fr\/sunovion-annonce-lapprobation-par-sante-canada-du-film-soluble-kynmobi-chlorhydrate-dapomorphine-pour-le-traitement-des-episodes-darret-de-la-maladie-de-parkinson\/#breadcrumblist"},"author":{"@id":"https:\/\/www.parkinson.ca\/fr\/author\/deactivatedusers\/#author"},"creator":{"@id":"https:\/\/www.parkinson.ca\/fr\/author\/deactivatedusers\/#author"},"datePublished":"2020-06-17T11:34:53+00:00","dateModified":"2025-01-17T23:07:58+00:00"},{"@type":"WebSite","@id":"https:\/\/www.parkinson.ca\/fr\/#website","url":"https:\/\/www.parkinson.ca\/fr\/","name":"Parkinson Canada","inLanguage":"fr-FR","publisher":{"@id":"https:\/\/www.parkinson.ca\/fr\/#organization"}}]},"og:locale":"fr_FR","og:site_name":"Parkinson Canada -","og:type":"article","og:title":"Sunovion annonce l\u2019approbation par Sant\u00e9 Canada du film soluble KYNMOBI\u2122 (chlorhydrate d\u2019apomorphine) pour le traitement des \u00e9pisodes d\u2019arr\u00eat de la maladie de Parkinson. - Parkinson Canada","og:description":"MISSISSAUGA, Ontario--(BUSINESS WIRE)-- Sunovion Pharmaceuticals Inc. (Sunovion) a annonc\u00e9 aujourd'hui que Sant\u00e9 Canada a approuv\u00e9 KYNMOBI\u2122 (apomorphine HCI) film soluble pour le traitement aigu et intermittent des \u00e9pisodes OFF chez les patients atteints de la maladie de Parkinson (MP). Les \u00e9pisodes OFF correspondent \u00e0 la r\u00e9apparition ou \u00e0 l'aggravation des sympt\u00f4mes de la maladie de","og:url":"https:\/\/www.parkinson.ca\/fr\/sunovion-annonce-lapprobation-par-sante-canada-du-film-soluble-kynmobi-chlorhydrate-dapomorphine-pour-le-traitement-des-episodes-darret-de-la-maladie-de-parkinson\/","og:image":"https:\/\/www.parkinson.ca\/wp-content\/uploads\/2025\/02\/Parkinson-Canada-featured-image.png","og:image:secure_url":"https:\/\/www.parkinson.ca\/wp-content\/uploads\/2025\/02\/Parkinson-Canada-featured-image.png","og:image:width":1000,"og:image:height":600,"article:published_time":"2020-06-17T11:34:53+00:00","article:modified_time":"2025-01-17T23:07:58+00:00","article:publisher":"https:\/\/facebook.com\/parkinsoncanada","twitter:card":"summary_large_image","twitter:site":"@parkinsoncanada","twitter:title":"Sunovion annonce l\u2019approbation par Sant\u00e9 Canada du film soluble KYNMOBI\u2122 (chlorhydrate d\u2019apomorphine) pour le traitement des \u00e9pisodes d\u2019arr\u00eat de la maladie de Parkinson. - Parkinson Canada","twitter:description":"MISSISSAUGA, Ontario--(BUSINESS WIRE)-- Sunovion Pharmaceuticals Inc. (Sunovion) a annonc\u00e9 aujourd'hui que Sant\u00e9 Canada a approuv\u00e9 KYNMOBI\u2122 (apomorphine HCI) film soluble pour le traitement aigu et intermittent des \u00e9pisodes OFF chez les patients atteints de la maladie de Parkinson (MP). Les \u00e9pisodes OFF correspondent \u00e0 la r\u00e9apparition ou \u00e0 l'aggravation des sympt\u00f4mes de la maladie de","twitter:creator":"@parkinsoncanada","twitter:image":"https:\/\/www.parkinson.ca\/wp-content\/uploads\/2025\/02\/Parkinson-Canada-featured-image.png"},"aioseo_meta_data":{"post_id":"46565","title":null,"description":null,"keywords":null,"keyphrases":null,"primary_term":null,"canonical_url":null,"og_title":null,"og_description":null,"og_object_type":"default","og_image_type":"default","og_image_url":null,"og_image_width":null,"og_image_height":null,"og_image_custom_url":null,"og_image_custom_fields":null,"og_video":null,"og_custom_url":null,"og_article_section":null,"og_article_tags":null,"twitter_use_og":false,"twitter_card":"default","twitter_image_type":"default","twitter_image_url":null,"twitter_image_custom_url":null,"twitter_image_custom_fields":null,"twitter_title":null,"twitter_description":null,"schema":{"blockGraphs":[],"customGraphs":[],"default":{"data":{"Article":[],"Course":[],"Dataset":[],"FAQPage":[],"Movie":[],"Person":[],"Product":[],"ProductReview":[],"Car":[],"Recipe":[],"Service":[],"SoftwareApplication":[],"WebPage":[]},"graphName":"","isEnabled":true},"graphs":[]},"schema_type":"default","schema_type_options":null,"pillar_content":false,"robots_default":true,"robots_noindex":false,"robots_noarchive":false,"robots_nosnippet":false,"robots_nofollow":false,"robots_noimageindex":false,"robots_noodp":false,"robots_notranslate":false,"robots_max_snippet":null,"robots_max_videopreview":null,"robots_max_imagepreview":"large","priority":null,"frequency":null,"local_seo":null,"breadcrumb_settings":null,"limit_modified_date":false,"ai":null,"created":"2025-01-28 11:21:12","updated":"2025-06-07 10:34:25","seo_analyzer_scan_date":null},"aioseo_breadcrumb":"<div class=\"aioseo-breadcrumbs\"><span class=\"aioseo-breadcrumb\">\n\t\t\t<a href=\"https:\/\/www.parkinson.ca\/fr\/\" title=\"Home\">Home<\/a>\n\t\t<\/span><span class=\"aioseo-breadcrumb-separator\">&raquo;<\/span><span class=\"aioseo-breadcrumb\">\n\t\t\t<a href=\"https:\/\/www.parkinson.ca\/fr\/category\/non-classe\/\" title=\"Non class\u00e9\">Non class\u00e9<\/a>\n\t\t<\/span><span class=\"aioseo-breadcrumb-separator\">&raquo;<\/span><span class=\"aioseo-breadcrumb\">\n\t\t\tSunovion annonce l\u2019approbation par Sant\u00e9 Canada du film soluble KYNMOBI\u2122 (chlorhydrate d\u2019apomorphine) pour le traitement des \u00e9pisodes d\u2019arr\u00eat de la maladie de Parkinson.\n\t\t<\/span><\/div>","aioseo_breadcrumb_json":[{"label":"Home","link":"https:\/\/www.parkinson.ca\/fr\/"},{"label":"Non class\u00e9","link":"https:\/\/www.parkinson.ca\/fr\/category\/non-classe\/"},{"label":"Sunovion annonce l&rsquo;approbation par Sant\u00e9 Canada du film soluble KYNMOBI\u2122 (chlorhydrate d&rsquo;apomorphine) pour le traitement des \u00e9pisodes d&rsquo;arr\u00eat de la maladie de Parkinson.","link":"https:\/\/www.parkinson.ca\/fr\/sunovion-annonce-lapprobation-par-sante-canada-du-film-soluble-kynmobi-chlorhydrate-dapomorphine-pour-le-traitement-des-episodes-darret-de-la-maladie-de-parkinson\/"}],"_links":{"self":[{"href":"https:\/\/www.parkinson.ca\/fr\/wp-json\/wp\/v2\/posts\/46565","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.parkinson.ca\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.parkinson.ca\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.parkinson.ca\/fr\/wp-json\/wp\/v2\/users\/67"}],"replies":[{"embeddable":true,"href":"https:\/\/www.parkinson.ca\/fr\/wp-json\/wp\/v2\/comments?post=46565"}],"version-history":[{"count":0,"href":"https:\/\/www.parkinson.ca\/fr\/wp-json\/wp\/v2\/posts\/46565\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.parkinson.ca\/fr\/wp-json\/wp\/v2\/media?parent=46565"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.parkinson.ca\/fr\/wp-json\/wp\/v2\/categories?post=46565"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.parkinson.ca\/fr\/wp-json\/wp\/v2\/tags?post=46565"},{"taxonomy":"audience","embeddable":true,"href":"https:\/\/www.parkinson.ca\/fr\/wp-json\/wp\/v2\/audience?post=46565"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}